Restricting these survival analyses to patients with KRAS WT tumours, very similar results were obtained [HR for OS from meta‐analysis of the two trials, 0.99, 95% CI 0.65, 1.51; p = 0.95; HR for PFS, 0.83, 95% CI 0.54, 1.28; p = 0.40], with no evidence for heterogeneity between studies. This evidence concerns the gene KRAS and neoplasm.